
Collegium Pharmaceutical (COLL) Stock Forecast & Price Target
Collegium Pharmaceutical (COLL) Analyst Ratings
Bulls say
Collegium Pharmaceutical is expected to have a strong performance over the next few years, as its product portfolio, which includes Jornay PM and Nucynta, has the potential for significant sales growth. The company is also expected to benefit from net profits from authorized generic versions of Nucynta in the future. Moreover, the company's strong projected top-line and expected increase in adjusted EBITDA for 2026, as well as potential BD activity, make it a worthwhile investment for long-term investors.
Bears say
Collegium Pharmaceutical is at risk due to potential generic erosion on their pain portfolio, limited future deal opportunities due to a recent balance sheet cleanup, and facing significant competition and headwinds with established products and generics which can impact their sales levels and reimbursements. Their recent update on Nucynta launch timing for both Nucynta ER and IR in 2026 also raises concerns about the sustainability of their financials.
This aggregate rating is based on analysts' research of Collegium Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Collegium Pharmaceutical (COLL) Analyst Forecast & Price Prediction
Start investing in Collegium Pharmaceutical (COLL)
Order type
Buy in
Order amount
Est. shares
0 shares